Med-IQ
Clinical Trial Endpoints for Macular Diseases
Webcast Webcast

Clinical Trial Endpoints for Macular Diseases


This activity was developed by Med-IQ in collaboration with Duke University Health System Department of Clinical Education and Professional Development.

Med-IQ      Duke Medicine
 

Time to Complete:
15 minutes
Released:
1/9/18
Expires:
1/8/19
PDF:

Maximum Credits:

0.25 AMA PRA Category 1 Credit(s)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Webcast Webcast
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.
Time to Complete:
15 minutes

Released:
1/9/18

Expires:
1/8/19

PDF:

Maximum Credits:
0.25 AMA PRA Category 1 Credit(s)
Share on:
Webcast Webcast
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Share on:


Time to Complete:
15 minutes
Released:
1/9/18
Expires:
1/8/19
PDF:


Maximum Credits:
0.25 AMA PRA Category 1 Credit(s)


Overview: In this accredited CME webcast, recorded live at the 2017 American Academy of Ophthalmology (AAO) annual meeting, expert faculty Nora Lad, MD, PhD, discusses clinical trials on biomarkers to detect early age-related macular degeneration and early treatment response.

Faculty

Eleonora (Nora) Lad, MD, PhD

Associate Professor of Ophthalmology

Director of Grading, Duke Reading Center

Duke Eye Center

Duke University Medical Center

Durham, NC


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

Eleonora (Nora) Lad, MD, PhD
Consulting fees/advisory boards: Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Stealth BioTherapeutics Inc.
Other (clinical studies): Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd.

The peer reviewers and activity planners have no financial relationships to disclose.
 

This activity has been approved for AMA PRA Category 1 Credit™.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.